Sign Up
OverviewAPI
Amgen's weight loss pipeline and upcoming Q4 results are being closely watched by investors. The company's plans to advance its GLP-1 receptor agonist maridebart cafraglutide and non-incretin-based oral therapy, AMG 786, are being scrutinized. Barclays highlights the potential value of Amgen's obesity prospects, which are expected to be a major focus in the upcoming results. However, some analysts have expressed doubts about the timeline for a Phase 1 readout for AMG 786. Amgen's financials, including its conservative earnings guidance and revenue expectations, are also closely monitored.

Ask a question